Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients may be due to insufficient drug penetration. As a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartelink, Imke H., Prideaux, Brendan, Krings, Gregor, Wilmes, Lisa, Lee, Pei Rong Evelyn, Bo, Pan, Hann, Byron, Coppé, Jean-Philippe, Heditsian, Diane, Swigart-Brown, Lamorna, Jones, Ella F., Magnitsky, Sergey, Keizer, Ron J, de Vries, Niels, Rosing, Hilde, Pawlowska, Nela, Thomas, Scott, Dhawan, Mallika, Aggarwal, Rahul, Munster, Pamela N., Esserman, Laura J., Ruan, Weiming, Wu, Alan H. B., Yee, Douglas, Dartois, Véronique, Savic, Radojka M., Wolf, Denise M., van ’t Veer, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594551/
https://www.ncbi.nlm.nih.gov/pubmed/28893315
http://dx.doi.org/10.1186/s13058-017-0896-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594551/
https://www.ncbi.nlm.nih.gov/pubmed/28893315
http://dx.doi.org/10.1186/s13058-017-0896-4

Ejemplares similares